David Lazar's OTC SPAC's/CUSTODIAN Plays

[9754LB851]

She sure is

might have just hit bottom .46

Also i think - the custodian Lazar bought shares here in the open market at ~ .70

cash balance is approximately $72.6 million

https://seekingalpha.com/article/4411632-synthetic-biologics-incs-syn-ceo-steve-shallcross-on-q4-2020-results-earnings-call-transcript?utm_campaign=twitter_automated&utm_content=article&utm_medium=social&utm_source=twitter_automated

I think No reverse merger coming here as someone mentioned w/SYN he just bought more than 5%.
Phase iii clinical trials & with other meds in the development,the company has 70+ million cash.. Anyways. Brutal markets. Great luck to you SS. Maybe next week markets rebound well

SYN-004 (ribaxamase)
Prevention of CDI, pathogenic overgrowth, AMR and aGVHD in allogeneic HCT recipients
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete

SYN-020
Prevention of enteropathy secondary to radiation therapy for pelvic cancers

https://www.syntheticbiologics.com/





Mar 1
SYN
Synthetic Genomics received a Notice of Allowance from the US Patent and Trademark Office for Application No. 16/518,360, titled: Recombinant Algal Microorganisms Having Increased Lipid Production, and Methods of Making and Using the Same.